Peter Diamandis
XPRIZE
Peter Diamandis is an entrepreneur and the founder of XPRIZE, a non-profit organization that designs and conducts competitions to incentivize technological development. His published research includes work on using artificial intelligence to develop deep markers of psychological and subjective age.
29 claims checked on air: 7 context 1 contradicted 2 overstated 13 supported 6 unverified
What they said on air - context
A National Cancer Institute study on 100,000 people found that stage 3 or 4 cancer diagnosis carries an 80% mortality rate, whereas stage 1 or 2 diagnosis carries an 80% to 99.9% survival rate.
"So, you know, the National Cancer Society did a study on 100,000 people, and they found that if you get something at stage 3 or stage 4, you have an 80% chance of dying—I like, look at it, 20% chance of living, or what to do. But their point is well made: it's really hard to turn around. If you get at stage 1 or 2, you have an 80 to 99.9% chance of survival." (said at 0:24:31)
The speaker conflates organizational names ('National Cancer Society', combining the American Cancer Society and the National Cancer Institute) and describes broad registry benchmarks as a single '100,000-person study.' Across large population-based registries such as the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and American Cancer Society annual reports, aggregate 5-year relative survival varies widely by cancer type. For many common cancers (such as breast, prostate, melanoma, and colorectal cancer), early-stage (localized, Stage I–II) detection is associated with 5-year relative survival rates between 80% and >99%, whereas advanced metastatic disease (distant, Stage IV) frequently exhibits 5-year relative survival of approximately 15% to 35% (corresponding to an ~65% to 85% mortality rate). However, survival differs dramatically by specific histology, organ of origin, and molecular subtypes rather than following a uniform cross-cancer rule.
Cellular NAD levels decline substantially after age 40 and into the 50s, reducing the activity of sirtuin enzymes.
"NAD is sort of a fuel in the cell that powers these sirtuins. And we can talk more in detail here, but the NAD in your in your mitochondria inside your cells, you know, is pretty good in your in your teens, 20s, and 30s, but then in your 40s into your 50s, it falls off rapidly. So just when you need more active sirtuins as the DNA damage is increasing, the fuel supply for the sirtuins starts plummeting, and then all of a sudden you're not able to, you know, control your epigenome and we get aging." (said at 0:30:36)
Nicotinamide adenine dinucleotide (NAD+) is an essential co-substrate for sirtuin enzymes (NAD+-dependent deacetylases) and poly(ADP-ribose) polymerases (PARPs). Human tissue studies demonstrate that cellular NAD+ levels and SIRT1 activity decline progressively with age, inversely correlating with accumulated DNA damage and PARP activation. However, characterizing this as a sudden 'plummet' or rapid drop-off specifically localized to one's 40s and 50s oversimplifies what human cross-sectional data show as a continuous, gradual decline across adulthood.
Average human life expectancy was under 40 years a century ago and is currently in the upper 70s.
"So a hundred years ago, the average lifespan was, you know, under 40. Today it's in the upper 70s" (said at 0:45:35)
The speaker's general characterization captures historical demographic trends, but combines global historical estimates with developed-world modern figures and refers to 'lifespan' rather than life expectancy at birth. A century ago (early 20th century), global life expectancy at birth was estimated to be under 35–40 years, heavily driven down by high infant and childhood mortality rather than a maximum biological lifespan ceiling of 40. Today, global average life expectancy at birth has reached approximately 73.5 years (low-to-mid 70s), while life expectancies in the upper 70s and 80s specifically characterize developed and high-income nations.
A study from the London School of Business, Harvard, and Oxford found that adding one year of healthy lifespan globally is worth $38 trillion to the global economy.
"there was uh about six months ago a study done out of London School of Business, Harvard, and Oxford that said adding just one year of healthy lifespan to every human on the planet is worth $38 trillion to the global economy." (said at 1:15:20)
A 2021 study published in Nature Aging by researchers from London Business School, the University of Oxford, and Harvard Medical School (Scott, Ellison, and Sinclair) estimated that slowing aging to increase life expectancy by 1 year is worth $38 trillion. However, this economic valuation—calculated using a Value of Statistical Life (VSL) framework—applied specifically to the United States population, rather than the entire global population or global gross domestic product.
50 years ago the global fertility rate was approximately 5.4 children per family, compared to about 2.4 globally today.
"Back 50 years ago, the average number of children per family was like 5.4 children per family. Today globally it's at about 2.4." (said at 1:16:25)
The speaker accurately describes the dramatic global demographic transition over recent decades, though with minor imprecisions in terminology and historical figures. Demographers measure this using the total fertility rate (TFR), defined as the average number of livebirths per woman across reproductive years, rather than "per family." Comprehensive demographic assessments (such as the Global Burden of Disease studies) show that global TFR was approximately 4.7 to 5.0 in the mid-20th century (and around 4.5–4.8 fifty years ago in the early 1970s) and has declined to approximately 2.3–2.4 in recent years (2.4 in 2017 and 2.31 in 2019).
The monoclonal antibody Repatha (evolocumab) blocks the PCSK9 protein in the liver and reduces LDL cholesterol levels by half.
"I take a monoclonal antibody called Repatha, that this antibody is manufactured in a vat in New York. And um I get an injector, and every two weeks I inject about 5 mL of this of this these antibodies into my into my my leg, and those antibodies go to my liver and they block a protein called PCSK9, which is the protein that produces LDL, the bad type of cholesterol in your bloodstream. And this Repatha reduces my cholesterol, my LDL levels by a half" (said at 1:21:45)
Evolocumab (Repatha) is a human monoclonal antibody that binds to and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), leading to an approximate 50% to 60% reduction in low-density lipoprotein (LDL) cholesterol. In the landmark phase 3 FOURIER trial involving 27,564 patients, evolocumab produced a 59% mean reduction in LDL cholesterol compared to placebo (PMID: 28304224). However, the speaker's description of the mechanism requires qualification: PCSK9 does not produce LDL cholesterol; rather, it binds to low-density lipoprotein receptors (LDLR) on hepatocytes and promotes their lysosomal degradation, reducing the liver's capacity to clear circulating LDL. Inhibiting PCSK9 prevents receptor breakdown, increasing hepatic clearance of LDL from the bloodstream. Additionally, standard biweekly dosing is 140 mg in 1.0 mL (rather than 5 mL).
Moderna designed its COVID-19 mRNA vaccine within 24 hours of receiving the SARS-CoV-2 genetic sequence from Wuhan.
"the sequence gets emailed over from Wuhan to our labs. I know from talking to Stéphane, there was a a vaccine designed within 24 hours." (said at 1:26:23)
Following the identification of the outbreak in Wuhan and the public release of the SARS-CoV-2 genomic sequence on January 11, 2020, researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center and Moderna finalized the sequence design for the mRNA-1273 vaccine within approximately 48 hours (by January 13, 2020). The claim accurately reflects the rapid, sequence-directed design process of the vaccine, though the design timeline was completed over approximately two days rather than strictly within 24 hours.
- context: An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development (Medical Science Monitor 2020) · cited 247x in the literature
"The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US)." (abstract, passage verified)
openalexfull study (doi)
Fact-checked episodes
Publications